Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Xilio Therapeutics, Inc. Common Stock (XLO)

Pharmaceutical Preparations

https://www.xiliotx.com

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

828 WINTER STREET
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/22/2021

Market Cap

37,175,016

Shares Outstanding

27,540,000

Weighted SO

27,528,926

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

CNTB --.--%

TYRA --.--%

RAPT --.--%

MLYS --.--%

EWTX --.--%

IKNA --.--%

DSGN --.--%

ELYM --.--%

Beta

-0.0560

Last Div

0.0000

Range

0.49-2.94

Chg

0.0158

Avg Vol

255650

Mkt Cap

37175016

Exch

NASDAQ

Country

US

Phone

617 430 4680

DCF Diff

-0.2902

DCF

1.1693

Div Yield

0.0000

P/S

7.0688

EV Multiple

0.4482

P/FV

1.4620

Div Yield %

0.0000

P/E

-0.7455

PEG

-0.0580

Payout

0.0000

Current Ratio

2.0188

Quick Ratio

2.0188

Cash Ratio

1.9396

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

256.7390

CCC

-256.7390

Gross Margin

0.6583

Op Margin

-12.6838

Pretax Margin

-12.4607

Net Margin

-12.4607

Eff Tax Rate

-0.0287

ROA

-0.7292

ROE

-1.7651

ROCE

-1.3020

NI/EBT

1.0000

EBT/EBIT

0.9824

EBIT/Rev

-12.6838

Debt Ratio

0.0966

D/E

0.2598

LT Debt/Cap

0.1846

Total Debt/Cap

0.2062

Int Coverage

-222.3467

CF/Debt

-1.9978

Equity Multi

2.6895

Rec Turnover

0.0000

Pay Turnover

1.4217

Inv Turnover

0.0000

FA Turnover

0.5257

Asset Turnover

0.0585

OCF/Share

-0.3003

FCF/Share

-0.3007

Cash/Share

1.2976

OCF/Sales

-3.2982

FCF/OCF

1.0012

CF Coverage

-1.9978

ST Coverage

-15.5421

CapEx Coverage

-825.9524

Div&CapEx Cov

-825.9524

P/BV

1.4620

P/B

1.4620

P/S

7.0688

P/E

-0.7455

P/FCF

-2.1407

P/OCF

-2.8166

P/CF

-2.8166

PEG

-0.0580

P/S

7.0688

EV Multiple

0.4482

P/FV

1.4620

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 05, 22:38 Xilio Therapeutics Announces Closing of $50.0 Million Public Offering GlobeNewswire Inc. Jan 08, 07:30 Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies GlobeNewswire Inc. Dec 07, 07:30 Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data GlobeNewswire Inc. Oct 31, 09:15 Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Revenue Product Segmentation